Yegnasew Takele
Overview
Explore the profile of Yegnasew Takele including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
344
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Takele Y, Mulaw T, Adem E, Shaw C, Franssen S, Womersley R, et al.
Cell Rep Med
. 2022 Feb;
3(1):100487.
PMID: 35106507
Visceral leishmaniasis (VL) has emerged as a clinically important opportunistic infection in HIV patients, as VL/HIV co-infected patients suffer from frequent VL relapse. Here, we follow cohorts of VL patients...
12.
Franssen S, Takele Y, Adem E, Sanders M, Muller I, Kropf P, et al.
mBio
. 2021 Jun;
12(3):e0097121.
PMID: 34182785
Visceral leishmaniasis (VL) is a fatal disease and a growing public health problem in East Africa, where Ethiopia has one of the highest VL burdens. The largest focus of VL...
13.
Vogt F, Mengesha B, Asmamaw H, Mekonnen T, Fikre H, Takele Y, et al.
Am J Trop Med Hyg
. 2018 Aug;
99(4):957-966.
PMID: 30084342
Diagnosis of visceral leishmaniasis (VL) and assessment of treatment response in human immunodeficiency virus (HIV)-coinfected patients still relies on invasive tissue aspiration. This hampers scale-up and decentralization of care in...
14.
van Griensven J, Mengesha B, Mekonnen T, Fikre H, Takele Y, Adem E, et al.
Front Cell Infect Microbiol
. 2018 Apr;
8:94.
PMID: 29651411
Biomarkers predicting the risk of VL treatment failure and relapse in VL/HIV coinfected patients are needed. Nested within a two-site clinical trial in Ethiopia (2011-2015), we conducted an exploratory study...
15.
Ferede G, Diro E, Getie S, Getnet G, Takele Y, Amsalu A, et al.
Malar Res Treat
. 2017 Sep;
2017:6816913.
PMID: 28932617
Background: Despite high prevalence of visceral leishmaniasis and malaria in the study area, their coinfection remains unknown. Therefore, this study was aimed to document VL-malaria coinfections and their associated factors....
16.
Tajebe F, Getahun M, Adem E, Hailu A, Lemma M, Fikre H, et al.
PLoS Negl Trop Dis
. 2017 Jul;
11(7):e0005727.
PMID: 28732017
Visceral leishmaniasis (VL) is a neglected tropical disease that affects the poorest communities and can cause substantial morbidity and mortality. Visceral leishmaniasis is characterized by the presence of Leishmania parasites...
17.
Yizengaw E, Getahun M, Tajebe F, Cruz Cervera E, Adem E, Mesfin G, et al.
Front Immunol
. 2016 Dec;
7:517.
PMID: 27965662
Immunologically, active visceral leishmaniasis (VL) is characterized by profound immunosuppression, severe systemic inflammatory responses, and an impaired capacity to control parasite replication. Neutrophils are highly versatile cells, which play a...
18.
Diro E, Yansouni C, Takele Y, Mengesha B, Lynen L, Hailu A, et al.
Am J Trop Med Hyg
. 2016 Nov;
96(1):190-196.
PMID: 27799651
Visceral leishmaniasis (VL) is a fatal parasitic disease. Unfortunately, diagnosis of VL in east Africa currently relies on aspiration of tissue from the spleen or bone marrow, which is painful...
19.
Adem E, Tajebe F, Getahun M, Kiflie A, Diro E, Hailu A, et al.
PLoS Negl Trop Dis
. 2016 Mar;
10(3):e0004468.
PMID: 26962865
One of the key immunological characteristics of active visceral leishmaniasis (VL) is a profound immunosuppression and impaired production of Interferon-γ (IFN-γ). However, recent studies from Bihar in India showed using...
20.
Diro E, Lynen L, Assefa M, Takele Y, Mengesha B, Adem E, et al.
PLoS Negl Trop Dis
. 2015 May;
9(5):e0003738.
PMID: 25965564
Background: Diagnostic guidelines for Visceral Leishmaniasis (VL) in the East African region are complex. Patients meeting the VL clinical case definition should be tested by rK39 rapid diagnostic test (RDT)...